Search Result

Results for "

difficile

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (1) Antibiotic (21) Apoptosis (5) ATP Synthase (1) Autophagy (1) Bacterial (45) Biochemical Assay Reagents (2) c-Fms (1) Caspase (1) Collagen (3) CRFR (2) DNA/RNA Synthesis (8) Endogenous Metabolite (4) ERK (1) Fungal (2) Gap Junction Protein (1) Isotope-Labeled Compounds (5) MDM-2/p53 (1) NF-κB (1) p38 MAPK (1) Parasite (3) Potassium Channel (1) Reactive Oxygen Species (ROS) (1) Reference Standards (8) Topoisomerase (2) Wnt (1)
By Research Areas:	Cancer (3) Infection (51) Inflammation/Immunology (11) Metabolic Disease (5) Neurological Disease (2)

By Targets:

Adenosine Receptor (1)

Antibiotic (21)

Apoptosis (5)

ATP Synthase (1)

Autophagy (1)

Bacterial (45)

Biochemical Assay Reagents (2)

c-Fms (1)

Caspase (1)

Collagen (3)

CRFR (2)

DNA/RNA Synthesis (8)

Endogenous Metabolite (4)

ERK (1)

Fungal (2)

Gap Junction Protein (1)

Isotope-Labeled Compounds (5)

MDM-2/p53 (1)

NF-κB (1)

p38 MAPK (1)

Parasite (3)

Potassium Channel (1)

Reactive Oxygen Species (ROS) (1)

Reference Standards (8)

Topoisomerase (2)

Wnt (1)

By Research Areas:

Cancer (3)

Infection (51)

Inflammation/Immunology (11)

Metabolic Disease (5)

Neurological Disease (2)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-17580

Fidaxomicin 5+ Cited Publications OPT-80; PAR-101	DNA/RNA Synthesis Bacterial Apoptosis Antibiotic	Infection
Fidaxomicin (OPT-80), a macrocyclic antibiotic, is an orally active and potent RNA polymerase inhibitor. Fidaxomicin has a narrow spectrum of antibacterial activity and a good anti-Clostridium difficile activity (MIC₉₀=0.12 μg/mL). Fidaxomicin can be used for Clostridium difficile infection (CDI) research .

HY-B0565

Ronidazole 2 Publications Verification	Parasite Bacterial	Infection
Ronidazole is a potent and orally active antiprotozoal and anti-microbial agent. Ronidazole acts as a veterinary agent against Tritrichomonas foetus in cats models. Ronidazole can be used the research of forhistomoniasis and swine dysentery .

HY-B0975

Penicillin V Potassium Phenoxymethylpenicillin potassium salt	Bacterial Antibiotic	Infection
Penicillin V Potassium (Phenoxymethylpenicillin potassium salt) is an orally active antibiotic. Penicillin V Potassium inhibits the growth of Streptococci, C. difficile and S. aureus. Penicillin V Potassium can be used for the research of otitis, sinusitis, pharyngitis and tonsillitis .

HY-B0975A

Penicillin V Phenoxymethylpenicillin	Antibiotic Bacterial	Infection
Penicillin V (Phenoxymethylpenicillin) is a potent and orally active antibiotic. Penicillin V shows antibacterial activity for Streptococci, Clostridium difficile and staphylococcus aureus. Penicillin V has the potential for the research of otitis, sinusitis, pharyngitis and tonsillitis .

HY-107830

Methyl cholate	Endogenous Metabolite Collagen	Infection Metabolic Disease
Methyl cholate is a bile acid analog and a specific inhibitor of TcdB toxin from Clostridioides difficile. Methyl cholate exerts a stronger selective inhibitory effect on TcdB than on TcdA. Methyl cholate induces conformational stabilization by binding to a unique site of TcdB, thereby blocking the binding of the toxin to host receptors and its self-processing process. Methyl cholate effectively protects human fibroblasts from TcdB-induced cytopathic effects. Methyl cholate exhibits dose-dependent anti-hepatic fibrosis activity in both cellular and zebrafish models, and significantly reduces the expression levels of α-SMA and COL-I. Methyl cholate is suitable for in-depth research in the fields of Clostridioides difficile infection and hepatic fibrosis .

HY-16753

Ridinilazole 1 Publications Verification SMT19969	Bacterial	Infection
Ridinilazole is a novel antibacterial with MICs range of 0.06-0.25 µg/mL (MIC₉₀=8 µg/mL) against C. difficile.

HY-P1137

10Panx 1 Publications Verification	Gap Junction Protein	Others
10Panx is a competitive inhibitor of selective Pannexin 1 (PANX1) channels. 10Panx blocks the opening of PANX1 channels, inhibits ATP release and downstream P2X7 receptor-mediated signaling pathways, thereby reducing cell death and inflammatory responses. 10Panx can be used in the study of diseases such as neuropathic pain, inflammatory bowel disease, and Clostridioides difficile infection. 10Panx can effectively reduce mechanical hyperalgesia and enhanced C-reflexes, and inhibit the expression of pro-inflammatory factors such as IL-6[1][2][3].

HY-128357

Ibezapolstat 4 Publications Verification ACX-362E; GLS-362E	Bacterial DNA/RNA Synthesis	Infection
Ibezapolstat (ACX-362E) is a first-in-class, orally active DNA polymerase IIIC (pol IIIC) inhibitor, with a K_i of 0.325 μM for the DNA pol IIIC from C. difficile. Ibezapolstat is developed for the research of C. difficile infection(CDI) .

HY-P9929

Bezlotoxumab 1 Publications Verification BLA761046; MBL-CDB1; MDX-1388	Bacterial	Infection
Bezlotoxumab (BLA761046; MBL-CDB1; MDX-1388) is a fully humanized IgG1/kappa monoclonal antibody directed against Clostridium difficile toxin B. Bezlotoxumab mediates the early reconstitution of gut microbiota to reduce the risk of recurrent Clostridium difficile infection (CDI). Bezlotoxumab can be used for the study of recurrent Clostridium difficile infection prevention .

HY-100436

Cadazolid ACT-179811	Bacterial Antibiotic	Infection
Cadazolid (ACT-179811) is a new oxazolidinone antibiotic with potent activity against Clostridium difficile.

HY-P1108A

Astressin 2B TFA 1 Publications Verification	CRFR	Neurological Disease Inflammation/Immunology
Astressin 2B TFA is a blood-brain barrier-impermeable, highly selective CRFR2 antagonist (rCRFR2, IC₅₀=0.57 nM). Astressin 2B TFA blocks the protective effects mediated by CRFR2, thereby exacerbating indomethacin (HY-14397)-induced hemorrhagic intestinal injury in rats. Astressin 2B TFA reverses the protective effects of Urocortin 1 against intestinal hypermotility, bacterial invasion and upregulation of inflammatory mediators. Astressin 2B TFA also blocks the anxiogenic effect of Urocortin 2 and attenuates stress-induced anxiety-related behaviors. In the Clostridioides difficile toxin A (C. difficile toxin A)-mediated enteritis model, Astressin 2B TFA mimics the phenotype of CRFR2-deficient mice, significantly exacerbating intestinal epithelial damage, edema, neutrophil migration and the expression of multiple proinflammatory cytokines. Astressin 2B TFA is an important tool molecule for investigating the intestinal protective mechanisms of CRFR2 .

HY-B1143

Broxaldine Brobenzoxaldine	Parasite Fungal Bacterial	Infection
Broxaldine (Brobenzoxaldine) is an antiprotozoal agent. Broxaldine inhibits Clostridium difficile with a MIC value of 4 µM, and has antifungal effects .

HY-P1108

Astressin 2B 1 Publications Verification	CRFR	Neurological Disease Inflammation/Immunology
Astressin 2B is a blood-brain barrier-impermeable, highly selective CRFR2 antagonist (rCRFR2, IC₅₀=0.57 nM). Astressin 2B blocks the protective effects mediated by CRFR2, thereby exacerbating indomethacin (HY-14397)-induced hemorrhagic intestinal injury in rats. Astressin 2B reverses the protective effects of Urocortin 1 against intestinal hypermotility, bacterial invasion and upregulation of inflammatory mediators. Astressin 2B also blocks the anxiogenic effect of Urocortin 2 and attenuates stress-induced anxiety-related behaviors. In the Clostridioides difficile toxin A (C. difficile toxin A)-mediated enteritis model, Astressin 2B mimics the phenotype of CRFR2-deficient mice, significantly exacerbating intestinal epithelial damage, edema, neutrophil migration and the expression of multiple proinflammatory cytokines. Astressin 2B is an important tool molecule for investigating the intestinal protective mechanisms of CRFR2 .

HY-112253

D-Fructose 1-phosphate	Endogenous Metabolite	Metabolic Disease
D-Fructose 1-phosphate is a key intermediate metabolite in the fructose metabolic pathway. As a key signaling molecule linking fructose metabolism and glucose metabolic regulation, D-Fructose 1-phosphate acts as an allosteric modulator to counteract the inhibitory effect of the glucokinase-regulatory protein complex, thereby finely regulating the direction of hepatic glucose metabolism at the substrate level .

HY-103249

Reutericyclin Reutericycline	Bacterial	Infection Metabolic Disease
Reutericyclin (Reutericycline) is an orally active antibacterial and anti-obesity agent that selectively inhibits Gram-positive bacteria. By selectively dissipating transmembrane potential, Reutericyclin exerts non-lytic bactericidal or bacteriostatic activity against pathogens such as Clostridium difficile and Staphylococcus aureus, and rapidly kills vegetative cells and spores of Clostridium difficile. Reutericyclin possesses favorable properties including resistance to enzymatic hydrolysis, iron-chelating function, and poor absorption by colonic epithelium. Reutericyclin not only eradicates staphylococcal biofilms and inhibits drug-resistant strains, but also counteracts Risperidone (HY-11018)-induced weight gain by inducing changes in gut microbiota composition and restoring energy utilization efficiency. Reutericyclin can be used in research related to Clostridium difficile infection, Risperidone-induced weight gain, and staphylococcal superficial skin infections .

HY-105099

Rifalazil KRM-1648; ABI-1648	Antibiotic DNA/RNA Synthesis Bacterial	Infection Inflammation/Immunology
Rifalazil (KRM-1648; ABI-1648), a rifamycin derivative, inhibits the bacterial DNA-dependent RNA polymerase and kills bacterial cells by blocking off the β-subunit in RNA polymerase . Rifalazil (KRM-1648; ABI-1648) is an antibiotic, exhibits high potency against mycobacteria, gram-positive bacteria, Helicobacter pylori, C. pneumoniae and C. trachomatis with MIC values from 0.00025 to 0.0025 μg/ml . Rifalazil (KRM-1648; ABI-1648) has the potential for the treatment of Chlamydia infection, Clostridium difficile associated diarrhea (CDAD), and tuberculosis (TB) .

HY-18324

CRS3123 1 Publications Verification REP-3123	Antibiotic	Inflammation/Immunology
CRS3123 is a potent and orally active narrow-spectrum antibiotic. CRS3123 inhibits bacterial methionyl-tRNA synthetase. CRS3123 has potent activity against Clostridium difficile (C. difficile) and aerobic Gram-positive bacteria but little activity against Gram-negative bacteria, including anaerobes. CRS3123 has the potential for the research of C. difficile infections .

HY-17580S

Fidaxomicin-d7	Isotope-Labeled Compounds DNA/RNA Synthesis Bacterial Apoptosis Antibiotic	Infection
Fidaxomicin-d₇ (OPT-80-D₇) is the deuterium labeled Fidaxomicin. Fidaxomicin (OPT-80), a macrocyclic RNA polymerase inhibitor, has a narrow spectrum of activity. Fidaxomicin selectively eradicates pathogenic Clostridium difficile with minimal disruption to the multiple species of bacteria that make up the normal, healthy intestinal flora .

HY-115440

CRS3123 dihydrochloride 1 Publications Verification REP-3123 dihydrochloride	Bacterial Antibiotic	Infection
CRS3123 (REP-3123) dihydrochloride, a fully synthetic antibacterial agent, potently inhibits methionyl-tRNA synthetase (MetRS) of Clostridioides difficile, inhibiting Clostridioides difficile toxin production and spore formation. CRS3123 dihydrochloride is an oral agent for the research of Clostridioides difficile infection (CDI) .

HY-172670

Spore germination-IN-1	Fungal	Infection
Spore germination-IN-1 (Compound 110) is an orally active spore germination inhibitor (IC₅₀: 14 μM). Spore germination-IN-1 specifically inhibits the enzymatic activities of mature SleC and CspB on spores (K_d: 12 and 8 μM). Spore germination-IN-1 can be used in studies against C. difficile .

HY-148041

ATPase-IN-2	ATP Synthase	Others
ATPase-IN-2 is an ATPase inhibitor with an IC₅₀ value of 0.9 μM. ATPase-IN-2 inhibits C. difficile toxin B (TcdB) glycohydrolase activity with an AC₅₀ value of 30.91 μM. ATPase-IN-2 can be used for the research of ATP-related .

HY-105017

Evodenoson ATL 313; DE 112	Adenosine Receptor	Infection Inflammation/Immunology
Evodenoson is a selective agonist of the A_2A adenosine receptor. Evodenoson’s primary actions include reducing inflammatory responses, decreasing intestinal fluid secretion, edema, tissue damage, and neutrophil infiltration induced by Clostridium difficile toxin A. Evodenoson’s protective effect is achieved by reducing myeloperoxidase (MPO) and adenosine deaminase (ADA) activities, and by lowering the production of tumor necrosis factor-alpha (TNF-α) .

HY-P99134

Anti-Mouse GM-CSF Antibody (MP1-22E9) 1 Publications Verification	c-Fms	Infection Inflammation/Immunology Cancer
Anti-Mouse GM-CSF Antibody (MP1-22E9) is a rat-derived anti-mouse GM-CSF IgG2a antibody inhibitor. Anti-Mouse GM-CSF Antibody (MP1-22E9) can neutralize GM-CSF. Anti-Mouse GM-CSF Antibody (MP1-22E9) can be used for the researches of cancer, infection inflammation and immunology, such as cholangiocarcinoma and arthritis .

HY-B0565R

Ronidazole (Standard)	Reference Standards Parasite Bacterial	Infection
Ronidazole (Standard) is the analytical standard of Ronidazole. This product is intended for research and analytical applications. Ronidazole is a potent and orally active antiprotozoal and anti-microbial agent. Ronidazole acts as a veterinary agent against Tritrichomonas foetus?in cats models. Ronidazole can be used the research of forhistomoniasis?and?swine?dysentery .

HY-156191

Cholic acid anilide	Bacterial	Infection
Cholic acid anilide, a Narylcholan-24-amide, is a potent inhibitor of C. difficile spore germination with an IC₅₀ value of 1.8 μM in the spore germination assay conducted in Sodium phosphate media containing 6 mM Taurocholate (HY-B1131) and 12 mM Glycine (HY-Y0966). Cholic acid anilide has the potential for C. difficile infections research .

HY-P11114

Periplanetasin-4	Bacterial p38 MAPK Reactive Oxygen Species (ROS) Apoptosis Caspase	Infection Inflammation/Immunology
Periplanetasin-4 is an antimicrobial peptide that can be derived from the American cockroach (Periplaneta americana). Periplanetasin-4 reduces cell rounding and apoptosis. Periplanetasin-4 blocks Clostridium difficile toxin A-induced ROS production and the activation of downstream p38 MAPK and p21. Periplanetasin-4 significantly increases mitochondrial calcium level, reduces DPH fluorescence intensity and vacuolar dysfunction in Candida albicans ATCC 90028 cells. Periplanetasin-4 significantly ameliorates toxin A-induced mucosal damage in the mouse gut. Periplanetasin-4 can be used for the study of colitis .

HY-B0975S1

Penicillin V-d5 potassium Phenoxymethylpenicillin-d5 potassium salt	Bacterial Antibiotic	Infection
Penicillin V-d₅ (potassium) is the deuterium labeled Penicillin V Potassium . Penicillin V Potassium (Phenoxymethylpenicillin potassium salt) is an orally active antibiotic. Penicillin V Potassium inhibits the growth of Streptococci, C. difficile and S. aureus. Penicillin V Potassium can be used for the research of otitis, sinusitis, pharyngitis and tonsillitis .

HY-P10204

FZD7 antagonist 1	Wnt	Cancer
FZD7 antagonist 1 (peptide 34) is a dFz7-21 analogue. FZD7 antagonist 1 is an FZD7 antagonist that inhibits the wnt3a with IC₅₀ value of 9.2 nM. FZD7 antagonist 1 blocks TcdB−FZD interaction via targeting FZD receptors .

HY-148578

CamA-IN-1	Bacterial	Infection
CamA-IN-1 is a *Clostridioides difficile-specific* DNA adenine methyltransferase (CamA) inhibitor. CamA-IN-1 has inhibitory for CamA with IC₅₀ and K_d** values of 0.4 μM and 0.2 μM, respectively. CamA-IN-1 can be used for the research of Clostridioides difficile infections (CDI) .

HY-17580R

Fidaxomicin (Standard) OPT-80 (Standard); PAR-101 (Standard)	Reference Standards DNA/RNA Synthesis Bacterial Apoptosis Antibiotic	Infection
Fidaxomicin (Standard) is the analytical standard of Fidaxomicin. This product is intended for research and analytical applications. Fidaxomicin (OPT-80), a macrocyclic antibiotic, is an orally active and potent RNA polymerase inhibitor. Fidaxomicin has a narrow spectrum of antibacterial activity and a good anti-Clostridium difficile activity (MIC₉₀=0.12 μg/mL). Fidaxomicin can be used for Clostridium difficile infection (CDI) research .

HY-B0975AR

Penicillin V (Standard) Phenoxymethylpenicillin (Standard)	Reference Standards Antibiotic Bacterial	Infection
Penicillin V (Standard) is the analytical standard of Penicillin V. This product is intended for research and analytical applications. Penicillin V (Phenoxymethylpenicillin) is a potent and orally active antibiotic. Penicillin V shows antibacterial activity for Streptococci, Clostridium difficile and staphylococcus aureus. Penicillin V has the potential for the research of otitis, sinusitis, pharyngitis and tonsillitis [4].

HY-159955

DC-159a	Bacterial	Infection
DC-159a is an 8-methoxyfluoroquinolone with broad-spectrum antimicrobial activity, especially against Gram-positive pathogens. DC-159a against Peptostreptococcus, Clostridium difficile, and Bacteroides fragilis with MIC₉₀ values of 0.5, 4, and 2 μg/mL, respectively .

HY-163142

Antibacterial agent 172	Bacterial	Infection
Antibacterial agent 172 (Compound 6a) is a <,i>Clostridioides difficile (Cd) SpoVD inhibitor (IC₅₀=89 nM) that effectively inhibits sporulation of Clostridioides difficile. Antibacterial agent 172 can be used in the study of bacterial infections .

HY-156283

Antibacterial agent 159	Antibiotic	Infection
Antibacterial agent 159 (Compound 6d) is an antibiotic. Antibacterial agent 159 can effective against impetigo and C. difficile infection (CDI). Antibacterial agent 159 has no observed recurrence for C. difficile and exertes a minimal impact on the beneficial gut microbiome .

HY-128357A

Ibezapolstat hydrochloride ACX-362E hydrochloride; GLS-362E hydrochloride	Bacterial DNA/RNA Synthesis	Infection
Ibezapolstat hydrochloride is a first-in-class, orally active DNA polymerase IIIC (pol IIIC) inhibitor, with a K_i of 0.325 μM for the DNA pol IIIC from C. difficile. Ibezapolstat hydrochloride is developed for the research of C. difficile infection(CDI) .

HY-N12228

Phenelfamycin E	Bacterial Antibiotic	Infection
Phenelfamycin E is an elfamycin-type antibiotic and is active against Gram-positive anaerobes, including Clostridium difficile. Phenelfamycin E can be used for anti-bacteria research .

HY-123354

SC 44914	Bacterial	Infection
SC 44914 is a quinoxaline compound with antibacterial effects. SC-44914 has activity against Campylobacter jejuni, C. coli, and Clostridium difficile .

HY-B0975R

Penicillin V Potassium (Standard) Phenoxymethylpenicillin potassium salt (Standard)	Reference Standards Bacterial Antibiotic	Infection
Penicillin V (Potassium) (Standard) is the analytical standard of Penicillin V (Potassium). This product is intended for research and analytical applications. Penicillin V Potassium (Phenoxymethylpenicillin potassium salt) is an orally active antibiotic. Penicillin V Potassium inhibits the growth of Streptococci, C. difficile and S. aureus. Penicillin V Potassium can be used for the research of otitis, sinusitis, pharyngitis and tonsillitis .

HY-105099R

Rifalazil (Standard) KRM-1648 (Standard); ABI-1648 (Standard)	Antibiotic Reference Standards DNA/RNA Synthesis Bacterial	Infection Inflammation/Immunology
Rifalazil (Standard) is the analytical standard of Rifalazil. This product is intended for research and analytical applications. Rifalazil (KRM-1648; ABI-1648), a rifamycin derivative, inhibits the bacterial DNA-dependent RNA polymerase and kills bacterial cells by blocking off the β-subunit in RNA polymerase[1]. Rifalazil (KRM-1648; ABI-1648) is an antibiotic, exhibits high potency against mycobacteria, gram-positive bacteria, Helicobacter pylori, C. pneumoniae and C. trachomatis with MIC values from 0.00025 to 0.0025 μg/ml[3]. Rifalazil (KRM-1648; ABI-1648) has the potential for the treatment of Chlamydia infection, Clostridium difficile associated diarrhea (CDAD), and tuberculosis (TB)[2].

HY-156282

Antibacterial agent 158	Bacterial	Infection
Antibacterial agent 158 (compound 6c), a Micrococcin analogue, and is effective against impetigo and C. difficile* infection* (CDI) .

HY-172768

SCUT1-2	Bacterial	Infection
SCUT1-2 is a bifunctional antibacterial agent with good oral bioavailability in mice (F=56.8%). SCUT1-2 can kill the vegetative cells of C. difficile with a MIC of 0.06-0.50 μg/mL, and inhibit spore germination in vitro. SCUT1-2 could alleviate the symptoms of weight loss and diarrhea in mice caused by C. difficile infection (CDI) and prevent recurrent CDI .

HY-W749146

Raja 42	Antibiotic Bacterial	Infection
Raja 42 is a gamma lactam antibiotic. Raja 42 is effective against a variety of different bacterias, including Gram-positive and Gram-negative bacteria, such as C. difficile strains .

HY-100436R

Cadazolid (Standard) ACT-179811 (Standard)	Reference Standards Bacterial Antibiotic	Infection
Cadazolid (Standard) is the analytical standard of Cadazolid. This product is intended for research and analytical applications. Cadazolid (ACT-179811) is a new oxazolidinone antibiotic with potent activity against Clostridium difficile.

HY-163042

HSGN-218	Bacterial	Infection
HSGN-218 is an antibacterial agent with low Caco-2 permeability. HSGN-218 efficiently inhibits the growth of different C. difficile species with MIC values ranging from 0.007 μM to 0.07 μM.

HY-B0975S

Penicillin V-13C6 potassium Phenoxymethylpenicillin-13C6 potassium salt	Isotope-Labeled Compounds Bacterial Antibiotic	Infection
Penicillin V- ¹³C₆ (potassium) is the ¹³C₆ labeled Penicillin V (potassium). Penicillin V Potassium (Phenoxymethylpenicillin potassium salt) is an orally active antibiotic. Penicillin V Potassium inhibits the growth of Streptococci, C. difficile and S. aureus. Penicillin V Potassium can be used for the research of otitis, sinusitis, pharyngitis and tonsillitis.

HY-W750848

Raja 42-d10	Isotope-Labeled Compounds Bacterial Antibiotic	Infection
Raja 42-d₁₀ is the deuterium labeled Raja 42 (HY-W749146). Raja 42 is a gamma lactam antibiotic. Raja 42 is effective against a variety of different bacterias, including Gram-positive and Gram-negative bacteria, such as C. difficile strains .

HY-149610

Antibacterial agent 156	Bacterial	Infection
Antibacterial agent 156 (Compound 57) is a selective and potent bactericidal against C. difficile and targets cell-wall synthesis. Antibacterial agent 156 exhibits bactericidal activity with the minimal inhibitory concentration of 0.5 μg/mL and 1 μg/mL against MIMIC50 (101 strains) and MIC90 (101 strains) .

HY-B0975AS

Penicillin V-d5	Isotope-Labeled Compounds Bacterial Antibiotic	Infection
Penicillin V-d₅ (Phenoxymethylpenicillin-d₅) is the deuterium labeled Penicillin V. Penicillin V (Phenoxymethylpenicillin) is an orally active antibiotic. Penicillin V inhibits the growth of Streptococci, C. difficile and S. aureus. Penicillin V can be used for the research of otitis, sinusitis, pharyngitis and tonsillitis .

HY-143455

Germination-IN-2	Bacterial	Inflammation/Immunology
Germination-IN-2 (compound 15) is a potent germination inhibitor with an IC₅₀ of 1.3 µM. Germination-IN-2 shows anti-germination activity with 3% germination rate .

HY-143454

Germination-IN-1	Others	Inflammation/Immunology
Germination-IN-1 (compound 11) is a potent germination inhibitor with an IC₅₀ of 4 µM. Germination-IN-2 shows anti-germination activity with 14% germination rate .

Cat. No.	Product Name	Target	Research Area

HY-P1137

10Panx 1 Publications Verification	Gap Junction Protein	Others
10Panx is a competitive inhibitor of selective Pannexin 1 (PANX1) channels. 10Panx blocks the opening of PANX1 channels, inhibits ATP release and downstream P2X7 receptor-mediated signaling pathways, thereby reducing cell death and inflammatory responses. 10Panx can be used in the study of diseases such as neuropathic pain, inflammatory bowel disease, and Clostridioides difficile infection. 10Panx can effectively reduce mechanical hyperalgesia and enhanced C-reflexes, and inhibit the expression of pro-inflammatory factors such as IL-6[1][2][3].

HY-P1108A

Astressin 2B TFA 1 Publications Verification	CRFR	Neurological Disease Inflammation/Immunology
Astressin 2B TFA is a blood-brain barrier-impermeable, highly selective CRFR2 antagonist (rCRFR2, IC₅₀=0.57 nM). Astressin 2B TFA blocks the protective effects mediated by CRFR2, thereby exacerbating indomethacin (HY-14397)-induced hemorrhagic intestinal injury in rats. Astressin 2B TFA reverses the protective effects of Urocortin 1 against intestinal hypermotility, bacterial invasion and upregulation of inflammatory mediators. Astressin 2B TFA also blocks the anxiogenic effect of Urocortin 2 and attenuates stress-induced anxiety-related behaviors. In the Clostridioides difficile toxin A (C. difficile toxin A)-mediated enteritis model, Astressin 2B TFA mimics the phenotype of CRFR2-deficient mice, significantly exacerbating intestinal epithelial damage, edema, neutrophil migration and the expression of multiple proinflammatory cytokines. Astressin 2B TFA is an important tool molecule for investigating the intestinal protective mechanisms of CRFR2 .

HY-P1108

Astressin 2B 1 Publications Verification	CRFR	Neurological Disease Inflammation/Immunology
Astressin 2B is a blood-brain barrier-impermeable, highly selective CRFR2 antagonist (rCRFR2, IC₅₀=0.57 nM). Astressin 2B blocks the protective effects mediated by CRFR2, thereby exacerbating indomethacin (HY-14397)-induced hemorrhagic intestinal injury in rats. Astressin 2B reverses the protective effects of Urocortin 1 against intestinal hypermotility, bacterial invasion and upregulation of inflammatory mediators. Astressin 2B also blocks the anxiogenic effect of Urocortin 2 and attenuates stress-induced anxiety-related behaviors. In the Clostridioides difficile toxin A (C. difficile toxin A)-mediated enteritis model, Astressin 2B mimics the phenotype of CRFR2-deficient mice, significantly exacerbating intestinal epithelial damage, edema, neutrophil migration and the expression of multiple proinflammatory cytokines. Astressin 2B is an important tool molecule for investigating the intestinal protective mechanisms of CRFR2 .

HY-P11114

Periplanetasin-4	Bacterial p38 MAPK Reactive Oxygen Species (ROS) Apoptosis Caspase	Infection Inflammation/Immunology
Periplanetasin-4 is an antimicrobial peptide that can be derived from the American cockroach (Periplaneta americana). Periplanetasin-4 reduces cell rounding and apoptosis. Periplanetasin-4 blocks Clostridium difficile toxin A-induced ROS production and the activation of downstream p38 MAPK and p21. Periplanetasin-4 significantly increases mitochondrial calcium level, reduces DPH fluorescence intensity and vacuolar dysfunction in Candida albicans ATCC 90028 cells. Periplanetasin-4 significantly ameliorates toxin A-induced mucosal damage in the mouse gut. Periplanetasin-4 can be used for the study of colitis .

HY-P10204

FZD7 antagonist 1	Wnt	Cancer
FZD7 antagonist 1 (peptide 34) is a dFz7-21 analogue. FZD7 antagonist 1 is an FZD7 antagonist that inhibits the wnt3a with IC₅₀ value of 9.2 nM. FZD7 antagonist 1 blocks TcdB−FZD interaction via targeting FZD receptors .

HY-P10914

D-CopA3	MDM-2/p53 Autophagy	Inflammation/Immunology Cancer
D-CopA3 is the inhibitor for MDM2 and the activator for p53 signaling pathway. D-CopA3 exhibits cytotoxicity in colorectal cancer cells HCT-116, LoVo, and RKO (IC₅₀=15-18 μM), induces JNK/Beclin-1 mediated autophagy. D-CopA3 downregulates the expression of cell cycle inhibitory protein p21Cip1/Waf1, enhances the mucosal barrier function and reduces penetration of inflammatory mediators. D-CopA3 exhibits anti-inflammtory activity in mouse C. difficile toxin A-induced acute enteritis models and DSS (HY-116282)-induced chronic colitis models. D-CopA3 exhibits antitumor efficacy in mouse HCT-116 xenograft models .

Cat. No.	Product Name	Target	Research Area	Image

HY-P9929

Bezlotoxumab 1 Publications Verification BLA761046; MBL-CDB1; MDX-1388	Bacterial	Infection
Bezlotoxumab (BLA761046; MBL-CDB1; MDX-1388) is a fully humanized IgG1/kappa monoclonal antibody directed against Clostridium difficile toxin B. Bezlotoxumab mediates the early reconstitution of gut microbiota to reduce the risk of recurrent Clostridium difficile infection (CDI). Bezlotoxumab can be used for the study of recurrent Clostridium difficile infection prevention .

HY-P99277

Actoxumab Anti-C. difficile Toxin A Recombinant Antibody	Inhibitory Antibodies	Infection
Actoxumab (Anti-C. difficile Toxin A Recombinant Antibody) is a antitoxin antibody against C. difficile toxin A by neutralizing TcdA. Actoxumab prevents both the damage to the gut wall and the inflammatory response, which are associated with C. difficile. Actoxumab has synergy effect with Bezlotoxumab (HY-P9929) targeting TcdB .

HY-P99134

Anti-Mouse GM-CSF Antibody (MP1-22E9) 1 Publications Verification	c-Fms	Infection Inflammation/Immunology Cancer
Anti-Mouse GM-CSF Antibody (MP1-22E9) is a rat-derived anti-mouse GM-CSF IgG2a antibody inhibitor. Anti-Mouse GM-CSF Antibody (MP1-22E9) can neutralize GM-CSF. Anti-Mouse GM-CSF Antibody (MP1-22E9) can be used for the researches of cancer, infection inflammation and immunology, such as cholangiocarcinoma and arthritis .

HY-P992123

Ombetoxabart AZD-5148	Bacterial	Infection
Ombetoxabart is a humanized IgG1-κ monoclonal antibody targeting TcdB (Clostridioides difficile toxin B), which exerts its function by neutralizing the toxicity of TcdB. Ombetoxabart can be used for the study of Clostridioides difficile infection .

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P79219

	*Toxin B/TcdB Protein, C. difficile* (His)** 2 Publications Verification Toxin B; Glucosyltransferase TcdB; toxB	Others	E. coli
	Toxin B/TcdB protein is the precursor of the cytotoxin TcdB, which can strategically destroy the colon epithelium and cause host inflammatory response and diarrhea in Clostridium difficile infection. Compared with TcdA, TcdB has higher virulence and is essential for eliciting host responses. Toxin B/TcdB Protein, C. difficile (His) is the recombinant Toxin B/TcdB protein, expressed by E. coli , with C-6*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-17580S

Fidaxomicin-d7
Fidaxomicin-d₇ (OPT-80-D₇) is the deuterium labeled Fidaxomicin. Fidaxomicin (OPT-80), a macrocyclic RNA polymerase inhibitor, has a narrow spectrum of activity. Fidaxomicin selectively eradicates pathogenic Clostridium difficile with minimal disruption to the multiple species of bacteria that make up the normal, healthy intestinal flora .

HY-B0975S1

Penicillin V-d5 potassium
Penicillin V-d₅ (potassium) is the deuterium labeled Penicillin V Potassium . Penicillin V Potassium (Phenoxymethylpenicillin potassium salt) is an orally active antibiotic. Penicillin V Potassium inhibits the growth of Streptococci, C. difficile and S. aureus. Penicillin V Potassium can be used for the research of otitis, sinusitis, pharyngitis and tonsillitis .

HY-B0975S

Penicillin V-13C6 potassium
Penicillin V- ¹³C₆ (potassium) is the ¹³C₆ labeled Penicillin V (potassium). Penicillin V Potassium (Phenoxymethylpenicillin potassium salt) is an orally active antibiotic. Penicillin V Potassium inhibits the growth of Streptococci, C. difficile and S. aureus. Penicillin V Potassium can be used for the research of otitis, sinusitis, pharyngitis and tonsillitis.

HY-W750848

Raja 42-d10
Raja 42-d₁₀ is the deuterium labeled Raja 42 (HY-W749146). Raja 42 is a gamma lactam antibiotic. Raja 42 is effective against a variety of different bacterias, including Gram-positive and Gram-negative bacteria, such as C. difficile strains .

HY-B0975AS

Penicillin V-d5
Penicillin V-d₅ (Phenoxymethylpenicillin-d₅) is the deuterium labeled Penicillin V. Penicillin V (Phenoxymethylpenicillin) is an orally active antibiotic. Penicillin V inhibits the growth of Streptococci, C. difficile and S. aureus. Penicillin V can be used for the research of otitis, sinusitis, pharyngitis and tonsillitis .

HY-W746556

Methyl cholate-d5

Methyl cholate-d₅ is the deuterium labeled Methyl cholate. Methyl cholate is a bile acid analog and a specific inhibitor of TcdB toxin from Clostridioides difficile. Methyl cholate exerts a stronger selective inhibitory effect on TcdB than on TcdA. Methyl cholate induces conformational stabilization by binding to a unique site of TcdB, thereby blocking the binding of the toxin to host receptors and its self-processing process. Methyl cholate effectively protects human fibroblasts from TcdB-induced cytopathic effects. Methyl cholate exhibits dose-dependent anti-hepatic fibrosis activity in both cellular and zebrafish models, and significantly reduces the expression levels of α-SMA and COL-I. Methyl cholate is suitable for in-depth research in the fields of Clostridioides difficile infection and hepatic fibrosis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

difficile

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Natural
Products